Cocrystal Pharma gets IRB approval for Phase 1b norovirus challenge study with CDI-988; enrollment starts Q1 2026

Cocrystal Pharma, Inc.

IRB approval from Emory University to initiate Phase 1b human challenge study with CDI-988 for norovirus prevention and treatment.
Enrollment expected to begin Q1 2026; study involves up to 40 healthy subjects ages 18-49.
CDI-988 is first oral broad-spectrum antiviral for norovirus; no approved treatments or vaccines currently exist.
Study is randomized, double-blind, placebo-controlled; primary endpoint is reduction in clinical symptoms.
Follows prior FDA clearance of IND and favorable Phase 1 safety data from August 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.